Sandeep Gurbuxani to Mutation
This is a "connection" page, showing publications Sandeep Gurbuxani has written about Mutation.
Connection Strength
0.811
-
Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults. Blood Cancer J. 2025 Aug 14; 15(1):138.
Score: 0.102
-
Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms. Blood Cancer J. 2024 06 18; 14(1):99.
Score: 0.094
-
Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis. Blood Cancer Discov. 2024 May 01; 5(3):164-179.
Score: 0.093
-
SETBP1 sets the stage. Blood. 2024 04 04; 143(14):1323-1324.
Score: 0.092
-
Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood. 2004 Jan 15; 103(2):399-406.
Score: 0.089
-
On a WHIM. Blood. 2013 Feb 07; 121(6):875.
Score: 0.043
-
Leukemia mutated proteins PHF6 and PHIP form a chromatin complex that represses acute myeloid leukemia stemness. Genes Dev. 2025 Oct 01; 39(19-20):1219-1240.
Score: 0.026
-
Malignant progression of preleukemic disorders. Blood. 2024 05 30; 143(22):2245-2255.
Score: 0.023
-
Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors. Br J Haematol. 2024 Apr; 204(4):1238-1242.
Score: 0.023
-
Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome. Blood Cells Mol Dis. 2003 Nov-Dec; 31(3):351-6.
Score: 0.022
-
Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. Haematologica. 2023 08 01; 108(8):2234-2239.
Score: 0.022
-
Oncogenic RAS promotes leukemic transformation of CUX1-deficient cells. Oncogene. 2023 03; 42(12):881-893.
Score: 0.021
-
Type I but Not Type II Calreticulin Mutations Activate the IRE1a/XBP1 Pathway of the Unfolded Protein Response to Drive Myeloproliferative Neoplasms. Blood Cancer Discov. 2022 07 06; 3(4):298-315.
Score: 0.020
-
Therapy-related myeloid neoplasms with normal karyotype show distinct genomic and clinical characteristics compared to their counterparts with abnormal karyotype. Br J Haematol. 2022 06; 197(6):736-744.
Score: 0.020
-
LKB1/STK11 Is a Tumor Suppressor in the Progression of Myeloproliferative Neoplasms. Cancer Discov. 2021 06; 11(6):1398-1410.
Score: 0.019
-
Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentations. Blood Adv. 2020 10 13; 4(19):4873-4886.
Score: 0.018
-
Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib. Br J Haematol. 2020 07; 190(1):e48-e51.
Score: 0.018
-
Eradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted miR-150 Nanoparticles. Cancer Res. 2016 08 01; 76(15):4470-80.
Score: 0.013
-
Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. Nat Med. 2015 Dec; 21(12):1473-80.
Score: 0.013
-
AKT is a therapeutic target in myeloproliferative neoplasms. Leukemia. 2013 Sep; 27(9):1882-90.
Score: 0.011
-
Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia. Cancer Cell. 2012 Oct 16; 22(4):524-35.
Score: 0.010
-
Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome. J Clin Invest. 2012 Mar; 122(3):948-62.
Score: 0.010
-
FOG-1-mediated recruitment of NuRD is required for cell lineage re-enforcement during haematopoiesis. EMBO J. 2010 Jan 20; 29(2):457-68.
Score: 0.009